Status:
COMPLETED
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
Lead Sponsor:
Pfizer
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-85 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease. The study will also evaluate the absorption and dis...
Eligibility Criteria
Inclusion
- Subjects must have Alzheimer's dementia with a Mini Mental State Examination score between 18-26, inclusive.
- Subjects must have a reliable caregiver.
- Subjects must be on Aricept
- Memantine is allowed if subjects are on a stable dose
- Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG, with no serious or unstable disease within the past 3 months.
Exclusion
- Subjects with clinically significant heart disease cannot participate.
- Subjects with a past or current history of seizures cannot participate.
Key Trial Info
Start Date :
October 26 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 5 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00988598
Start Date
October 26 2009
End Date
July 5 2010
Last Update
November 19 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Glendale Adventist Medical Center
Glendale, California, United States, 91206
2
University of Florida - Center for Clinical Trials Research
Gainesville, Florida, United States, 32608
3
MD Clinical
Hallandale, Florida, United States, 33009